Use of trigonal agonist having activities to all of glucagon, glp-1, and gip receptors in treatment of sequelae following respiratory infectious diseases
AssigneeHanmi Pharm. Co., Ltd.
InventorsJong Suk LEE, Jung Kuk LEE, Seon Myeong LEE, Sang Hyun LEE, Jeong A KIM, Euh Lim OH, Chong Yoon LIM
Life of this patent
Estimating the term…
Abstract
Provided is use of a trigonal agonist having activities to all of glucagon, GLP-1, and GIP receptors, and/or a conjugate thereof in the prevention or treatment of sequelae following respiratory infectious diseases.
Claims16
A method for preventing or treating sequelae following respiratory infectious diseases, comprising administering a pharmaceutical composition to a patient in need thereof, the pharmaceutical composition comprising a pharmaceutically acceptable excipient and a pharmaceutically effective amount of a peptide including any one amino acid sequence of SEQ ID NOS:
- 1 to 102.
Dependencies are inferred from the claim text.